By Dr. Tanner
Prevalence
Guideline recommendations used in this article have been adapted from
Etiology
Complications
Abstracted from Western Journal of Medicine January 2002;176:23-28
A nice summary of the status of obesity and some of the important reasons it should be treated.We have been using EFT quite successfully in our practice to help people address the nearly universally emotional stresses that contribute to the problem.
Related Articles:
Each Daily Soda Pop Increases Obesity Risk 60% Lower Your Obesity Hormone with Diet and Exercise
Each Daily Soda Pop Increases Obesity Risk 60%
Lower Your Obesity Hormone with Diet and Exercise
References
National Heart, Lung and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and Treatment of Over-weight and Obesity in Adults. Bethesda, MD: National Institutes of Health; 1998 .
Douketis JD, Feightner JW, Attia J, Feldman WF. Periodic health examination, 1999 update: 1. Detection, prevention, and treatment of obesity. Canadian Task Force on Preventive Health. CMAJ 1999; 160: 513 -525.[Medline]
National Center for Health Statistics. Third National Health and Nutrition Examination Survey 1988-1994. Atlanta, GA: Centers for Disease Control and Prevention; 1996 .
Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999;282: 1519 -1522.[Medline]
Rowland ML. Self-reported weight and height. Am J Clin Nutr 1990;52: 1125 -1133.[Medline]
Yanovski JA, Yanovski SZ. Recent advances in basic obesity research. JAMA 1999;282: 1504 -1506.[Medline]
Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282: 1568 -1575.[Medline]
Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995; 332: 621 -628.[Abstract/Full Text]
Adapted from Bray GA. Contemporary Diagnosis and Management of Obesity. Newtown, PA: Handbooks in Health Care; 1998. Original data: Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation on Obesity. Geneva: World Health Organization; June 1997.
Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523 -1529.[Medline]
Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body-mass index and mortality. N Engl J Med 1998;338: 1 -7.[Abstract/Full Text]
Mikhail N, Golub MS, Tuck ML. Obesity and hypertension. Prog Cardiovasc Dis 1999; 42: 39 -58.[Medline]
Teramae CY, Connolly HM, Grogan M, Miller FA Jr. Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience. Mayo Clin Proc 2000; 75: 456 -461. A study of 191 patients with a history of exposure to fenfluramine and phentermine or dexfenfluramine alone, referred for echocardiography during 1997. Of the 191 patients, 60 (31%) had valvulopathy. Mild aortic regurgitation was the most common lesion. Five patients underwent surgical repair or replacement. Pulmonary hypertension was found in 25 patients (13%).[Medline]
Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343: 1826 -1832. A study of 702 patients with recent subarachnoid or intracerebral hemorrhage and 376 controls. In women, the adjusted odds ratio was 15.9 for the association of hemorrhagic stroke with the use of appetite suppressants containing phenylpropanolamin[Abstract/Full Text]
Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996;4: 263 -270.[Abstract]
Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. Efficacy and tolerability of sibutramine in obese persons: a dose ranging study. Int J Obes Relat Metab Disord 1998; 22: 32 -38.[Medline]
Drug Facts & Comparisons 2000. 54th ed. St Louis: Facts & Comparisons; 2000. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352: 167 -172.[Medline]
Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1 year study. Am J Clin Nutr 1999;69: 1108 -1116.[Abstract/Full Text]
Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens 1998; 16: 2013 -2017.[Medline]
Hvizdos KM, Markham A. Orlistat: a review of its use in the management of obesity. Drugs 1999; 58: 743 -760.[Medline]
Brolin RE. Critical analysis of results: weight loss and quality of data. Am J Clin Nutr 1992; 55: S577 -S581. In 98 obese patients who underwent gastric bypass, average BMI was reduced from 50.2 to 34.1, with maximum improvement occurring 18 months after the operation. In a series of 182 surgical patients, 95% of obesity-related medical problems i